MDGL vs. BIIB, UTHR, INCY, BMRN, NBIX, EXEL, EXAS, RGEN, HALO, and ALKS
Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Alkermes (ALKS). These companies are all part of the "biotechnology" industry.
Madrigal Pharmaceuticals vs.
Madrigal Pharmaceuticals (NASDAQ:MDGL) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.
Madrigal Pharmaceuticals presently has a consensus price target of $375.75, indicating a potential upside of 19.87%. Biogen has a consensus price target of $213.33, indicating a potential upside of 50.54%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Madrigal Pharmaceuticals.
Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Madrigal Pharmaceuticals had 23 more articles in the media than Biogen. MarketBeat recorded 44 mentions for Madrigal Pharmaceuticals and 21 mentions for Biogen. Biogen's average media sentiment score of 1.14 beat Madrigal Pharmaceuticals' score of 0.73 indicating that Biogen is being referred to more favorably in the news media.
Madrigal Pharmaceuticals has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Comparatively, Biogen has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500.
Biogen received 1354 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 71.47% of users gave Biogen an outperform vote while only 67.94% of users gave Madrigal Pharmaceuticals an outperform vote.
Biogen has a net margin of 16.87% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Biogen's return on equity of 14.98% beat Madrigal Pharmaceuticals' return on equity.
98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 22.8% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Biogen beats Madrigal Pharmaceuticals on 13 of the 19 factors compared between the two stocks.
Get Madrigal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Madrigal Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MDGL) was last updated on 3/4/2025 by MarketBeat.com Staff
Free MDGL Stock Alerts